Jónas Einarsson
Chairman bei ULTIMOVACS ASA
Profil
Jónas Einarsson is currently the Chief Executive Officer at Radiumhospitalets Forskningsstiftelse, Chairman at Ultimovacs ASA, Director at Nucligen AS, and Director at Occi Holding AS.
Previously, he served as the Chief Executive Officer at Oslo Cancer Cluster NCE, Chairman at Circio Holding ASA, Chairman at Hubro Therapeutics AS, Director at Biomolex AS, Independent Director at Nordic Nanovector ASA, and Director at Oncoinvent AS.
He holds a doctorate degree from the University of Oslo and Reykjavik University.
Aktive Positionen von Jónas Einarsson
Unternehmen | Position | Beginn |
---|---|---|
ULTIMOVACS ASA | Chairman | 26.01.2011 |
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Chief Executive Officer | 15.06.2009 |
Nucligen AS | Director/Board Member | - |
Occi Holding AS
Occi Holding AS Real Estate DevelopmentFinance Occi Holding AS is a Norwegian company that leases real estate properties. The private company is based in Hamar, Norway. | Director/Board Member | - |
Ehemalige bekannte Positionen von Jónas Einarsson
Unternehmen | Position | Ende |
---|---|---|
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Director/Board Member | 04.02.2022 |
Hubro Therapeutics AS
Hubro Therapeutics AS BiotechnologyHealth Technology Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway. | Chairman | - |
CIRCIO HOLDING ASA | Chairman | 30.11.2017 |
Biomolex AS
Biomolex AS Medical SpecialtiesHealth Technology Biomolex AS develops and delivers imaging systems for digital autoradiography. It offers Biomolex 700, a digital imager for protein micro-array analysis, including kinase analyses, protein interaction assays, single istotope deoxyribonucleic acid array analyses, micro analyses; and tissue imaging applications, such as foreign genetic material delivery, tissue specific distributions, uptake of antibodies, and uptake of labeled bio-molecules. The company was founded in May 2001 and is headquartered in Oslo, Norway. | Director/Board Member | - |
THOR MEDICAL | Director/Board Member | - |
Ausbildung von Jónas Einarsson
University of Oslo | Doctorate Degree |
Reykjavik University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ULTIMOVACS ASA | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Private Unternehmen | 8 |
---|---|
Oslo Cancer Cluster NCE
Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Oslo Cancer Cluster NCE is an oncology research firm that specializes in developing cancer diagnostics and medicines. The private company is based in Oslo, Norway. | Commercial Services |
Radiumhospitalets Forskningsstiftelse
Radiumhospitalets Forskningsstiftelse Financial ConglomeratesFinance Radiumhospitalets Forskningsstiftelse invests in companies from Nordic research institutions. It is a pre-seed investor and project developer focused on cancer. It strengthens cancer research at Rikshospitalet University Hospital, including The Norwegian Radium Hospital. It provides Oslo Cancer Cluster with the necessary infrastructure and management team, as well. The company was founded in 1986 and is headquartered in Lysaker, Norway. | Finance |
Biomolex AS
Biomolex AS Medical SpecialtiesHealth Technology Biomolex AS develops and delivers imaging systems for digital autoradiography. It offers Biomolex 700, a digital imager for protein micro-array analysis, including kinase analyses, protein interaction assays, single istotope deoxyribonucleic acid array analyses, micro analyses; and tissue imaging applications, such as foreign genetic material delivery, tissue specific distributions, uptake of antibodies, and uptake of labeled bio-molecules. The company was founded in May 2001 and is headquartered in Oslo, Norway. | Health Technology |
Nordic Nanovector ASA
Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
Nucligen AS | |
Hubro Therapeutics AS
Hubro Therapeutics AS BiotechnologyHealth Technology Hubro Therapeutics AS develops and trades biomedical products and services. It offers a technology platform for cancer vaccines targeting stomach and colon cancer. The company was founded by Jon Amund Eriksen on November 20, 2018 and is headquartered in Oslo, Norway. | Health Technology |
Occi Holding AS
Occi Holding AS Real Estate DevelopmentFinance Occi Holding AS is a Norwegian company that leases real estate properties. The private company is based in Hamar, Norway. | Finance |